Clinical Trial Update: Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease [Phase 3]

View source ↗

Summary

A Phase III randomized trial of the anti-TNF chimeric monoclonal antibody cA2 for enterocutaneous fistulae in Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: FDA Office of Orphan Products Development | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED